Since MTX and mercaptopurine are two main antileukemic agents used during maintenance therapy in current ALL protocols, we also performed deep sequencing of NT5C2 and PRPS1, two important genes in the thiopurine pathway16–18, in this cohort of patients. This evidence concerns the gene PRPS1 and acute lymphoblastic leukemia.